Yongqian Shu

机构：Jiangsu Cancer Hospital, Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0002-3034-685X

发表论文 102 篇 · 总被引 5784 次 · h-index 38

代表论文

• The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications (2023 · Experimental Hematology and Oncology · 被引 49)
• First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study (2024 · Signal Transduction and Targeted Therapy · 被引 43)
• LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m6A‐YTHDF2‐dependent manner (2023 · Clinical and Translational Medicine · 被引 43)
• Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study (2022 · Journal of Thoracic Oncology · 被引 27)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 17)
• METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer (2024 · World Journal of Surgical Oncology · 被引 13)